Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial

Fig. 1

a Dietary Phe tolerance during the extension period. b Dietary Phe tolerance (mg/kg/day) change in baseline during the extension period. The Month 1 visit in the extension period was only for patients who entered the extension period and who had received only a Phe-restricted diet in the 26-week study period. *Baselines are not contemporaneous; for the ‘sapropterin continuous’ group, the baseline was 26 weeks prior to that for the ‘sapropterin extension’ group (indicated by the dotted blue line in a). †p < 0.05 versus Baseline. ‡p < 0.001 versus Baseline. Phe phenylalanine

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172